Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | LOX | P28300 | 1/20 | 0.57 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.57 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.57 |
| ▸ | GRM5 | P41594 | 2/20 | 0.49 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | GHSR | Q92847 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | MGMT | P16455 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3676475 | 0.79 | ENPP2 (0.40) | RECQLLOXL2ENPP2KDM4ETDP1 | |
| SCHEMBL11940508 | 0.78 | ENPP2 (0.37) | RECQLLOXLOXL3LOXL2GRM5 | |
| SCHEMBL29894545 | 0.76 | LOXL2 (0.57) | LOXL2ENPP2KDM4ETDP1MMP3 | |
| SCHEMBL1925278 | 0.76 | GRM5 (0.46) | GRM5ENPP2KDM4ETDP1MMP3 | |
| SCHEMBL897832 | 0.76 | LOXL2 (0.57) | LOXL2ENPP2KDM4ETDP1MMP3 | |
| SCHEMBL29841095 | 0.76 | GRM5 (0.46) | GRM5ENPP2KDM4ETDP1MMP3 | |
| SCHEMBL1670797 | 0.76 | ENPP2 (0.38) | LOXLOXL2ENPP2KDM4ETDP1 | |
| SCHEMBL13183449 | 0.76 | ENPP2 (0.38) | RECQLLOXLOXL3LOXL2ENPP2 | |
| SCHEMBL30834457 | 0.76 | ENPP2 (0.38) | LOXLOXL2ENPP2KDM4ETDP1 | |
| SCHEMBL25673666 | 0.76 | MYC (0.39) | GRM5ENPP2KDM4ETDP1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12527779-B2 | Prostaglandin E2 (PGE2) EP4 receptor antagonists | DOMAIN THERAPEUTICS (FR) | 2026-01-20 | — | — | US | disclosed |
| EP-4038052-B1 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2024-02-07 | — | — | EP | disclosed |
| US-20220378772-A1 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2022-12-01 | — | — | US | disclosed |
| EP-4038052-A2 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | Domain Therapeutics (FR) | 2022-08-10 | — | — | EP | disclosed |
| CN-114555573-A | Prostaglandin E2(PGE2)EP4Receptor antagonists | 多曼治疗学公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2021064189-A2 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2021-04-08 | — | — | WO | disclosed |
| US-20160031812-A1 | SEPIAPTERIN REDUCTASE INHIBITORS FOR THE TREATMENT OF PAIN | SOLACE PHARMACEUTICALS UK LTD. (GB) | 2016-02-04 | — | — | US | disclosed |
| US-20160031812-A1 | SEPIAPTERIN REDUCTASE INHIBITORS FOR THE TREATMENT OF PAIN | SOLACE PHARMACEUTICALS UK LTD. (GB) | 2016-02-04 | — | — | US | disclosed |
| US-9169234-B2 | Sepiapterin reductase inhibitors for the treatment of pain | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2015-10-27 | — | — | US | disclosed |
| US-9169234-B2 | Sepiapterin reductase inhibitors for the treatment of pain | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2015-10-27 | — | — | US | disclosed |
| EP-2646438-A1 | 3-HETARYL-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS PDK1 INHIBITORS | Merck Patent GmbH (DE) | 2013-10-09 | — | — | EP | disclosed |
| US-20130245355-A1 | 3-HETARYL-SUBSTITUTED PYRROLO[2,3 B]PYRIDINE DERIVATIVES AS PDK1 INHIBITORS | MERCK PATENT GMBH (DE) | 2013-09-19 | — | — | US | disclosed |
| CN-103228657-A | 3-heteroaryl-substituted pyrrolo [2,3-b ] pyridine derivatives as PDK1 inhibitors | MERCK PATENT GMBH | 2013-07-31 | — | — | CN | disclosed |
| US-20120322800-A1 | Sepiapterin Reductase Inhibitors For The Treatment of Pain | SOLACE PHARMACEUTICALS UK LTD. (GB) | 2012-12-20 | — | — | US | disclosed |
| US-20120322800-A1 | Sepiapterin Reductase Inhibitors For The Treatment of Pain | SOLACE PHARMACEUTICALS UK LTD. (GB) | 2012-12-20 | — | — | US | disclosed |
| WO-2012072200-A1 | 3-HETARYL-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS PDK1 INHIBITORS | MERCK PATENT GMBH (DE) | 2012-06-07 | — | — | WO | disclosed |
| WO-2011047156-A1 | SEPIAPTERIN REDUCTASE INHIBITORS FOR THE TREATMENT OF PAIN | HERCULES TECHNOLOGY MANAGEMENT CO V, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031812-A1 | SEPIAPTERIN REDUCTASE INHIBITORS FOR THE TREATMENT OF PAIN | SPR, QDPR, SRR | RECQL 1493/4885LOX 2826/4885LOXL3 4356/4885 |
| US-12527779-B2 | Prostaglandin E2 (PGE2) EP4 receptor antagonists | PTGER1, PTGER4, PTGER3 | RECQL 2755/4885LOX 1190/4885LOXL3 383/4885 |
| US-20120322800-A1 | Sepiapterin Reductase Inhibitors For The Treatment of Pain | SPR, QDPR, SRR | RECQL 1493/4885LOX 2826/4885LOXL3 4356/4885 |
| US-20130245355-A1 | 3-HETARYL-SUBSTITUTED PYRROLO[2,3 B]PYRIDINE DERIVATIVES AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | RECQL 675/4885LOX 3378/4885LOXL3 4045/4885 |
| US-20220378772-A1 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | PTGER4, PTGER1, PTGER2 | RECQL 2595/4885LOX 1793/4885LOXL3 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.